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Prophylactic Defibrillator Implantation — 




Most patients who have an out-of-hospital cardi-
ac arrest do not survive. Thus, the use of a prophy-
lactic implantable cardioverter–defibrillator (ICD)
for the primary prevention of sudden death is a con-
ceptually attractive option for high-risk patients.
Several clinical trials have previously shown that
ICDs reduced mortality in patients with coronary
artery disease who had not yet had a life-threatening
arrhythmia and who were selected on the basis of





 In the past year, four
multicenter clinical trials have helped refine the se-
lection of appropriate patients for ICD therapy. In ad-
dition to confirming and expanding data on patients
with chronic coronary artery disease, these studies
added new information about the treatment of pa-






















included patients with left ventricular dysfunction
regardless of cause and used the presence of heart
failure despite medical therapy and a left ventricu-
lar ejection fraction of less than 36 percent as an
entry criterion. The trial convincingly showed that
amiodarone does not decrease mortality among
patients with left ventricular dysfunction and heart
failure. The study also showed that patients who
received an ICD have a better outcome than those
who were treated with medical therapies, includ-
ing angiotensin-converting–enzyme inhibitors, an-
giotensin-receptor blockers, and beta-blockers. The
study confirmed the effectiveness of ICDs in pro-
longing survival among patients with heart failure
and coronary disease, although the benefit was
smaller than that seen in prior studies, perhaps be-





Only one large study had previously examined
the ability of the ICD to decrease mortality among
patients with nonischemic cardiomyopathy. The De-
fibrillators in NonIschemic Cardiomyopathy Treat-
ment Evaluation (DEFINITE) study showed a rela-
tive 35 percent decrease in overall mortality with
the use of ICD therapy, a difference that did not





there was a 27 percent relative decrease in mortal-
ity among patients with nonischemic cardiomy-
opathy. The results of these two studies are broadly
consistent and suggest that ICDs can improve sur-
vival among patients with nonischemic cardiomy-
opathy and severe left ventricular dysfunction.
Although the results of SCD-HeFT are generally
consistent with previous clinical trials, there are
some differences that require further investigation.
As noted by the authors, the benefit of the ICD in
SCD-HeFT appeared to be more marked in patients
with less severe congestive heart failure (New York
Heart Association class II) than it did in those with
class III heart failure — a finding that differed from
those of other trials. Other studies have shown that
the benefit of the ICD either did not vary according
to heart-failure class or was greater among patients
with class III congestive heart failure. The SCD-
HeFT investigators believe that this difference may
be a statistical aberration. To investigate this hypoth-
esis further, it will be necessary to analyze data on
the relative benefits of ICD among patients with is-
chemic and nonischemic cardiomyopathy who have
class II and class III congestive heart failure.
Although the ICD has been shown to be benefi-
cial in patients with chronic left ventricular dysfunc-
tion, this is not the case when the ICD is used im-





therapy for the primary prevention of sudden death
in patients with left ventricular dysfunction should
be considered a long-term rather than a short-term
intervention.
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The addition of a left ventricular lead to provide
resynchronization therapy has been shown to im-
prove heart failure and decrease mortality among





 Patients with class III congestive
heart failure who meet indications for the prophy-
lactic use of an ICD and have wide QRS complexes
should receive resynchronization therapy with an
ICD. There are not yet sufficient data to recommend
such therapy for patients with class II congestive
heart failure and wide QRS complexes or for patients
with narrow QRS complexes but with evidence of
mechanical dyssynchrony. ICD therapy is not spe-
cifically recommended for the primary prevention
of sudden death for patients with class IV congestive
heart failure, since the competing risk of progressive
pump failure may outweigh the survival benefit from
rapid termination of ventricular tachyarrhythmias.
However, since some patients who receive resyn-
chronization therapy will have improvement in their
heart failure, the potential benefits of such therapy
in this population should be studied further.
Although ICDs have been shown to be lifesav-
ing, they are expensive. The cost (including follow-
up) may reach as much as $40,000, even if single-
lead, “low-cost” ICDs are used. The effect of routine
prophylactic use of ICDs on health care costs in the





cent preliminary analysis of data from SCD-HeFT
suggests that ICDs are indeed cost-effective on the




 The Center for
Medicare and Medicaid Services has recently sug-
gested in a preliminary coverage decision that pa-
tients with left ventricular dysfunction and an ejec-
tion fraction of less than 31 percent should be
eligible to receive a single-chamber ICD as long as
they are enrolled in a prospective registry, as dis-









proposed coverage decision is a reasonable compro-
mise between ensuring that patients at highest risk
receive ICD therapy and avoiding a large escalation
in health care costs. It is based on post hoc analyses
of SCD-HeFT and DEFINITE, in both of which the
benefit of ICDs appeared to be less in patients with
left ventricular ejection fractions of 31 to 35 percent
(Al-Khatib S: personal communication).
Although the addition of an atrial lead to an
ICD could theoretically decrease the incidence of
inappropriate ICD shocks, there have been no pro-
spective studies showing convincing clinical ben-
efit through the addition of an atrial lead. Thus,
until more data are available, implanting single-
chamber ICDs in most patients who receive a pro-
phylactic ICD is appropriate. However, allowing atri-
al leads to be added for arrhythmia discrimination
and therapy in patients with documented supraven-
ticular tachyarrhythmias seems reasonable. Addi-
tional data regarding outcome from a registry of
patients receiving ICDs will be beneficial. Howev-
er, whether the data in this registry will be suffi-
ciently comprehensive to permit meaningful out-
come analyses will take several years to determine.
How should physicians apply the results of the
recent ICD trials in clinical practice? Patients with
ejection fractions of less than 31 percent should be
considered for a single-chamber ICD to improve
their survival. Resynchronization therapy should be
used when appropriate. Patients with ejection frac-
tions of 31 to 40 percent pose a more difficult treat-
ment challenge. For patients with coronary dis-
ease, data from some trials support the use of





 For patients with nonische-
mic cardiomyopathy, reimbursement guidelines
and clinical judgment should be used to evaluate
the risk–benefit ratio of the use of ICDs for patients
with an ejection fraction of 31 to 35 percent, and the
use of ICDs is probably not beneficial for patients
with an ejection fraction of more than 35 percent.
Although the ICD is effective in reducing mor-
tality among patients with left ventricular dysfunc-
tion, it may also result in morbidity, including a
high incidence of inappropriate shocks. Not all pa-
tients with left ventricular dysfunction should im-
mediately receive an ICD. However, physicians
should evaluate and discuss the risk–benefit ratio
for each patient regardless of the cause of heart
failure, keeping in mind that evidence now sup-
ports the concept that ICDs will prolong life and
should be used in most patients with severe left
ventricular dysfunction.
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to identify patients with coronary artery disease who are at risk for
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In the treatment of cardiovascular disease, clini-
cians commonly are caught between the compet-
ing considerations of cardiovascular benefit and
gastrointestinal risks. Low-dose aspirin (325 mg
or less daily) lowers the risk of cardiovascular and
cerebrovascular thrombotic events. Aspirin pre-
vents thromboses and blocks platelet aggregation
through inhibition of the cyclooxygenase enzyme,
thereby reducing thromboxane synthesis. Owing to
the inhibition of cyclooxygenase in the gastrointes-
tinal tract, aspirin also causes gastrointestinal ulcer-
ation and major bleeding, which limit its useful-
ness as an antithrombotic agent.
The risk of gastrointestinal bleeding generally





 Although the gastrointesti-
nal risks associated with aspirin can be reduced by




even the lowest doses have considerable risks —





 and the subtherapeutic dose of 10 mg
daily substantially inhibits gastric cyclooxygenase




 Thus, it is unlikely
that there is a daily dose of aspirin that has anti-
thrombotic efficacy without gastrointestinal risks.
A common clinical dilemma is how to manage
patients who need antiplatelet therapy but are also
at high risk for gastrointestinal bleeding, an exam-
ple being patients with a recent history of upper gas-
trointestinal bleeding induced by aspirin or other
nonsteroidal antiinflammatory (NSAID) drugs. Cur-
rent cardiology guidelines recommend clopidogrel






an effective antithrombotic agent because it blocks
the platelet activation of adenosine diphosphate
(ADP) by irreversibly binding to the ADP receptors
of platelets; this, in turn, prevents the ADP-depen-
dent activation of the glycoprotein IIb/IIIa com-
plex, the primary platelet receptor for fibrinogen.
In a randomized, prospective study of the efficacy
of 75 mg of clopidogrel given daily as compared
with 325 mg of aspirin for the secondary preven-
tion of thrombotic vascular events, clopidogrel was
marginally more effective than aspirin and resulted
in a moderately lower rate of gastrointestinal bleed-





evaluations of healthy volunteers at one week, clo-
pidogrel caused less gastroduodenal damage than




Several factors increase the risk of gastrointes-
tinal complications with the use of NSAIDs such as
aspirin. These include a history of ulcer or gastro-
intestinal complications, increased age, congestive





 Among these factors, a his-
tory of gastrointestinal bleeding is associated with
the highest risk of recurrent gastrointestinal bleed-





al wisdom suggests that clopidogrel should be a
safer, nonulcerogenic alternative for patients at high
risk for aspirin-induced ulcers. For those at highest
risk because of a history of gastrointestinal bleed-
ing, however, the risk of subsequent bleeding with
the use of clopidogrel had not been evaluated pro-
spectively. Furthermore, a small, retrospective study
suggested that a history of gastrointestinal bleed-
ing was an important risk factor for gastrointes-
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